KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Astrid Lièvre, Jean‐Baptiste Bachet, Delphine Le Corre et al. · Cancer Research · 2006
The anti-epidermal growth factor receptor (anti-EGFR) cetuximab has been proven to be efficient in metastatic colorectal cancer. The molecular mechanisms underlying the clinical response to this drug remain unknown. Genetic alterations of the intracellular effectors involved in EGFR-related signaling pathways may have an effect on response to this targeted therapy. In this study, tumors from 30 metastatic colorectal cancer patients treated by cetuximab were screened for KRAS, BRAF, and PIK3CA mutation by direct sequencing and for EGFR copy number by chromogenic in situ hybridization. Eleven of the 30 patients (37%) responded to cetuximab. A KRAS mutation was found in 13 tumors (43%) and was significantly associated with the absence of response to cetuximab (KRAS mutation in 0% of the 11 responder patients versus 68.4% of the 19 nonresponder patients; P = 0.0003). The overall survival of patients without KRAS mutation in their tumor was significantly higher compared with those patients with a mutated tumor (P = 0.016; median, 16.3 versus 6.9 months). An increased EGFR copy number was found in 3 patients (10%) and was significantly associated with an objective tumor response to cetuximab (P = 0.04). In conclusion, in this study, KRAS mutations are a predictor of resistance to cetuximab therapy and are associated with a worse prognosis. The EGFR amplification, which is not as frequent as initially reported, is also associated with response to this treatment.
Cited by 2,232 works. doi:10.1158/0008-5472.can-06-0191
Authors
- Astrid Lièvre
- Jean‐Baptiste Bachet
- Delphine Le Corre
- Valérie Boige
- Bruno Landi
- Jean‐François Emile
- Gorana Tomasic
- Christophe Penna
- Michel Pierre Ducreux
- Philippe R Rougier
- Frederique Madeleine Penault-Llorca
- Pierre Laurent‐Puig
References
- Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
- High Frequency of Mutations of the PIK3CA Gene in Human Cancers
- KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
- Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor
- Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study
- Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry
- Kirsten ras Mutations in Patients With Colorectal Cancer: the Multicenter "RASCAL" Study
- The Price Tag on Progress — Chemotherapy for Colorectal Cancer
- Molecular Alterations in Tumors and Response to Combination Chemotherapy with Gefitinib for Advanced Colorectal Cancer
- Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study